Pemvidutide
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About Pemvidutide
Pemvidutide is a GLP-1/glucagon dual receptor agonist being developed by Altimmune, showing Phase II weight loss of approximately 15% over 48 weeks with a notable advantage of preserving lean muscle mass — a key differentiator versus pure GLP-1 agents. Its glucagon component increases energy expenditure and fat oxidation while the GLP-1 component manages appetite and glucose. Early data suggests a favorable body composition profile compared to semaglutide.
Science
Mechanism of Action
Balanced co-agonism at GLP-1 receptors (appetite suppression, insulin secretion) and glucagon receptors (thermogenesis, fat oxidation, hepatic lipid metabolism) with a ratio designed to maximize fat loss while minimizing lean tissue catabolism.
Dosing
Typical Protocol
1.2–2.4 mg subcutaneous injection once weekly; Phase II dose range.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Pemvidutide is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.